Stephen D. Gillies, Ph.D. Founder, President and CEO
Dr. Gillies is an accomplished scientist and business executive.
He is an expert on recombinant antibodies and immunotherapy and inventor of core platform technologies, Immunocytokines and Fc-X, for which there are several clinical projects in development with various pharmaceutical companies, research institutes, and government agencies.
Prior to founding Provenance Biopharmaceuticals Corp., Dr Gillies was founding President of Lexigen Pharmaceuticals Corp. and led the company's acquisition by Merck KGaA.
While at Merck KGaA, Dr. Gillies led the global pharmaceutical company's pre-clinical oncology research.
Previously, he was vice president of research at Damon Biotech and Abbott Biotech Inc., where he oversaw development of recombinant antibodies and pro-urokinase, an anti-clotting protein.
During the course of his
scientific career, Dr. Gillies
has led multiple therapeutic candidates into clinical development for HIV/AIDS and cancer.
These include engineered antibodies, NCEs and immunocytokines.
Dr. Gillies serves on the Board of Directors of Galenea Corp. and Potentia Pharmaceuticals, Inc.
has his M.S. degree and Ph.D.
from the College of Medicine and Dentistry
, Rutgers University
B.S. degree from the University of Massachusetts
Stephen D. Gillies, Ph.D. Founder, CEO.
See bio under Management above
Dr. Raubitschek has had a strong interest in immunocytokines for many years and has recently collaborated with Dr. Gillies
to create and develop the DI-Leu16-IL2 immunocytokine.
Dr. Sondel is a long-term collaborator of Dr. Gillies
working both on pre-clinical proof-of-principle studies, as well as a main driver of the Phase I and II studies of the anti-GD2 targeting immunocytokine, hu14.18-IL2.
Prior to work with immunocytokines, Dr. Sondel has been involved in the early clinical studies of IL-2 and worked with Dr. Gillies
in the early U.S. studies of the parent antibody, ch14.18, in neuroblastoma and melanoma patients.
Doctors Sondel and Gillies are co-authors on more than 10 peer-reviewed journal articles.
and Dr. Reisfeld have been collaborators for more than twenty years.
In fact, the first immunocytokines created by Dr. Gillies
utilized antibodies (14.18 and KS-1/4) first isolated in Dr. Reisfeld's laboratory in the 1980's.